PDF(Pubmed)
Abstract：
The rapidly evolving landscape of biomarkers for colorectal cancer (CRC) necessitates an integrative, updated repository. In response, we constructed the Colorectal Cancer Biomarker Database (CBD), which collected and displayed the curated biomedicine information for 870 CRC biomarkers in the previous study. Building on CBD, we have now developed CBD2, which includes information on 1569 newly reported biomarkers derived from different biological sources (DNA, RNA, protein, and others) and clinical applications (diagnosis, treatment, and prognosis). CBD2 also incorporates information on nonbiomarkers that have been identified as unsuitable for use as biomarkers in CRC. A key new feature of CBD2 is its network analysis function, by which users can investigate the visible and topological network between biomarkers and identify their relevant pathways. CBD2 also allows users to query a series of chemicals, drug combinations, or multiple targets, to enable multidrug, multitarget, multipathway analyses, toward facilitating the design of polypharmacological treatments for CRC. CBD2 is freely available at http://www.eyeseeworld.com/cbd.
摘要：
大肠癌（CRC）生物标志物的快速发展的景观需要一个综合的，更新的存储库。作为回应,我们建立了结直肠癌生物标志物数据库（CBD），它收集并显示了先前研究中870个CRC生物标志物的精选生物医学信息。建立在CBD上，我们现在已经开发了CBD2，其中包括来自不同生物来源的1569个新报告的生物标志物的信息（DNA，RNA,蛋白质，和其他)和临床应用(诊断，治疗,和预后）。CBD2还包含关于已被鉴定为不适合用作CRC中的生物标志物的非生物标志物的信息。CBD2的一个关键新功能是其网络分析功能，通过它，用户可以研究生物标志物之间的可见和拓扑网络，并确定其相关路径。CBD2还允许用户查询一系列化学品，药物组合，或多个目标，为了实现多种药物，多目标,多途径分析，促进CRC多药物治疗的设计。CBD2可在http://www上免费获得。eyeseeworld.com/cbd.
